WO2014177510A3 - Polymer conjugates of indolocarbazole compounds in the treatment of pruritus - Google Patents

Polymer conjugates of indolocarbazole compounds in the treatment of pruritus Download PDF

Info

Publication number
WO2014177510A3
WO2014177510A3 PCT/EP2014/058584 EP2014058584W WO2014177510A3 WO 2014177510 A3 WO2014177510 A3 WO 2014177510A3 EP 2014058584 W EP2014058584 W EP 2014058584W WO 2014177510 A3 WO2014177510 A3 WO 2014177510A3
Authority
WO
WIPO (PCT)
Prior art keywords
pruritus
treatment
polymer conjugates
indolocarbazole compounds
indolocarbazole
Prior art date
Application number
PCT/EP2014/058584
Other languages
French (fr)
Other versions
WO2014177510A2 (en
Inventor
Silvio Traversa
David ROBLIN
Eliot FORSTER
Luisa Bertarione Rava Rossa
Valentina Mainero
Original Assignee
Creabilis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creabilis Sa filed Critical Creabilis Sa
Publication of WO2014177510A2 publication Critical patent/WO2014177510A2/en
Publication of WO2014177510A3 publication Critical patent/WO2014177510A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to the novel use of polymer conjugates of a class of indolocarbazole compounds for the prevention, alleviation or/and treatment of pruritus, particularly of pruritus associated with or caused by dermatological diseases.
PCT/EP2014/058584 2013-05-03 2014-04-28 Polymer conjugates of indolocarbazole compounds in the treatment of pruritus WO2014177510A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819200P 2013-05-03 2013-05-03
US61/819200 2013-05-03

Publications (2)

Publication Number Publication Date
WO2014177510A2 WO2014177510A2 (en) 2014-11-06
WO2014177510A3 true WO2014177510A3 (en) 2015-01-22

Family

ID=50624582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/058584 WO2014177510A2 (en) 2013-05-03 2014-04-28 Polymer conjugates of indolocarbazole compounds in the treatment of pruritus

Country Status (1)

Country Link
WO (1) WO2014177510A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693729B (en) * 2015-12-08 2017-12-22 贵州省中国科学院天然产物化学重点实验室 Indoles simultaneously [3,2 a] carbazole derivates and its application
WO2018208369A1 (en) * 2017-05-10 2018-11-15 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
WO2020023387A1 (en) * 2018-07-23 2020-01-30 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022999A1 (en) * 2005-08-25 2007-03-01 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
WO2008054292A1 (en) * 2006-11-01 2008-05-08 Astrazeneca Ab Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2010072795A1 (en) * 2008-12-22 2010-07-01 Creabilis S.A. Synthesis of polymer conjugates of indolocarbazole compounds
WO2011130195A1 (en) * 2010-04-12 2011-10-20 Somalogic, Inc. APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022999A1 (en) * 2005-08-25 2007-03-01 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
WO2008054292A1 (en) * 2006-11-01 2008-05-08 Astrazeneca Ab Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
WO2010072795A1 (en) * 2008-12-22 2010-07-01 Creabilis S.A. Synthesis of polymer conjugates of indolocarbazole compounds
WO2011130195A1 (en) * 2010-04-12 2011-10-20 Somalogic, Inc. APTAMERS TO β-NGF AND THEIR USE IN TREATING β-NGF MEDIATED DISEASES AND DISORDERS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREWS S W ET AL: "InhibitorsTrkA, TrkB and TrkC are effective in models of atopic dermatitis and allergic skin disease", vol. 133, no. Supplement 1, 1 May 2013 (2013-05-01), pages S19, XP008173385, ISSN: 0022-202X, Retrieved from the Internet <URL:http://www.nature.com/jid/journal/v133/n1s/pdf/jid201396a.pdf> DOI: 10.1038/JID.2013.95 *
ANONYMOUS: "NCT01808157: A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis", CLINICALTRIALS.GOV ARCHIVE, 8 March 2013 (2013-03-08), XP055153524, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT01808157/2013_03_08> [retrieved on 20141118] *
CHIRICOZZI ANDREA ET AL: "Effective topical agents and emerging perspectives in the treatment of psoriasis", EXPERT REVIEW OF DERMATOLOGY, EXPERT REVIEWS LTD, GB, vol. 7, no. 3, 1 June 2012 (2012-06-01), pages 283 - 293, XP008173389, ISSN: 1746-9872, DOI: 10.1586/EDM.12.18 *
TAKANO N ET AL: "Effects of high-affinity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model", BRITISH JOURNAL OF DERMATOLOGY, vol. 156, no. 2, February 2007 (2007-02-01), pages 241 - 246, XP002732744, ISSN: 0007-0963 *
YASUAKI HASHIMOTO ET AL: "CFTR-deficiency renders mice highly susceptible to cutaneous symptoms during mite infestation", LABORATORY INVESTIGATION, vol. 91, no. 4, 6 December 2010 (2010-12-06), pages 509 - 518, XP055153353, ISSN: 0023-6837, DOI: 10.1038/labinvest.2010.193 *

Also Published As

Publication number Publication date
WO2014177510A2 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
JO3343B1 (en) Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
TWD161529S (en) Therapeutic lamp
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3065768A4 (en) Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
EP3035992A4 (en) Compositions, methods and systems for the treatment of cutaneous disorders
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2013117744A3 (en) Methods of treating fibrosis
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
CO7160080A2 (en) Lipid compositions of racecadot
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
EP2991733A4 (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
WO2014140911A3 (en) Diagnostic and therapeutic methods relating to microrna-144
WO2014177510A3 (en) Polymer conjugates of indolocarbazole compounds in the treatment of pruritus
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
EP2948143A4 (en) Use of phenoxypropylamine compounds to treat depression
WO2014152917A3 (en) Physiological ligands for gpr139
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
WO2014056779A8 (en) Drug for the prophylaxis and treatment of a neurodegenerative disease

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14720124

Country of ref document: EP

Kind code of ref document: A2